Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHA NASDAQ:IMNN NASDAQ:INMB NASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$8.22-4.5%$9.62$0.23▼$8.36$32.42M2.79602,475 shs15,987 shsIMNNImunon$2.02+0.5%$2.65$1.95▼$27.65$8.45M1.9554,893 shs33,598 shsINMBINmune Bio$1.22-1.6%$1.37$1.09▼$11.64$32.97M1.03529,316 shs256,860 shsLSTALisata Therapeutics$3.46-0.6%$3.68$1.81▼$5.07$31.69M0.81172,870 shs91,440 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma0.00%-11.52%-18.13%+27.84%+148.34%IMNNImunon+0.50%-5.61%-25.74%-35.05%-89.87%INMBINmune Bio-1.61%-14.08%-14.69%-14.08%-84.05%LSTALisata Therapeutics-0.57%-0.57%+9.84%-31.21%+31.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$8.22-4.5%$9.62$0.23▼$8.36$32.42M2.79602,475 shs15,987 shsIMNNImunon$2.02+0.5%$2.65$1.95▼$27.65$8.45M1.9554,893 shs33,598 shsINMBINmune Bio$1.22-1.6%$1.37$1.09▼$11.64$32.97M1.03529,316 shs256,860 shsLSTALisata Therapeutics$3.46-0.6%$3.68$1.81▼$5.07$31.69M0.81172,870 shs91,440 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma0.00%-11.52%-18.13%+27.84%+148.34%IMNNImunon+0.50%-5.61%-25.74%-35.05%-89.87%INMBINmune Bio-1.61%-14.08%-14.69%-14.08%-84.05%LSTALisata Therapeutics-0.57%-0.57%+9.84%-31.21%+31.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHAAthira Pharma 1.00Sell$4.00-51.34% DownsideIMNNImunon 2.00Hold$10.00395.05% UpsideINMBINmune Bio 2.17Hold$8.00555.74% UpsideLSTALisata Therapeutics 1.67Reduce$15.00333.53% UpsideCurrent Analyst Ratings BreakdownLatest IMNN, INMB, ATHA, and LSTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026LSTALisata Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LSTALisata Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/21/2026IMNNImunon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026LSTALisata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$10.004/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/11/2026INMBINmune Bio Lucid Cap MktsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/AIMNNImunonN/AN/AN/AN/A$2.30 per shareN/AINMBINmune Bio$50K648.55N/AN/A$0.88 per share1.39LSTALisata Therapeutics$170K185.42N/AN/A$1.66 per share2.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHAAthira Pharma-$96.94M-$9.68N/AN/AN/AN/A-107.06%-89.89%N/AIMNNImunon-$14.49M-$5.16N/AN/AN/AN/A-341.23%-153.79%8/4/2026 (Estimated)INMBINmune Bio-$45.93M-$1.67N/AN/AN/AN/A-103.03%-77.66%8/6/2026 (Estimated)LSTALisata Therapeutics-$16.59M-$1.86N/AN/AN/AN/A-103.54%-83.08%8/6/2026 (Estimated)Latest IMNN, INMB, ATHA, and LSTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IMNNImunon-$1.2150-$0.84+$0.3750-$0.84N/AN/A5/11/2026Q1 2026LSTALisata TherapeuticsN/A-$0.50N/A-$0.50N/AN/A5/7/2026Q1 2026INMBINmune Bio-$0.2450-$0.20+$0.0450-$0.20$1.11 millionN/A3/31/2026Q4 2025IMNNImunon-$1.43-$1.29+$0.14-$1.30($0.73) millionN/A3/30/2026Q4 2025INMBINmune Bio-$0.27-$0.18+$0.09-$0.18($0.01) millionN/A3/12/2026Q4 2025LSTALisata Therapeutics-$0.74-$0.33+$0.41-$0.33N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATHAAthira PharmaN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHAAthira PharmaN/A9.709.70IMNNImunonN/A1.591.59INMBINmune BioN/A4.244.24LSTALisata TherapeuticsN/A4.234.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHAAthira Pharma57.12%IMNNImunon4.47%INMBINmune Bio12.72%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipATHAAthira Pharma19.80%IMNNImunon2.83%INMBINmune Bio21.40%LSTALisata Therapeutics9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHAAthira Pharma403.94 million3.16 millionNo DataIMNNImunon304.20 million4.08 millionNot OptionableINMBINmune Bio1026.58 million20.90 millionOptionableLSTALisata Therapeutics309.11 million8.28 millionNot OptionableIMNN, INMB, ATHA, and LSTA HeadlinesRecent News About These CompaniesLisata Therapeutics Announces Tender Offer from Kuva Acquisition Corp at $4.00 per Share Plus Contingent Value Rights10 minutes ago | quiverquant.comQLisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.41 minutes ago | globenewswire.comKuva and Lisata Therapeutics Tender Offer UpdateJune 1, 2026 | tennessean.comTHC Wainwright & Co. downgrades Lisata Therapeutics (LSTA)May 16, 2026 | msn.comLisata Therapeutics Amends Kuva Labs Merger Agreement TimelineMay 9, 2026 | theglobeandmail.comHalper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their ShareholdersMay 4, 2026 | globenewswire.comLisata Therapeutics Delays Tender Offer Launch in MergerApril 3, 2026 | tipranks.comLeading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum CommunicationsMarch 26, 2026 | businesswire.comLisata Therapeutics shares up 20% as Kuva Labs acquisition advancesMarch 10, 2026 | finance.yahoo.comLisata Therapeutics to be acquired by Kuva LabsMarch 9, 2026 | proactiveinvestors.comShareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersMarch 9, 2026 | prnewswire.comLisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.March 6, 2026 | globenewswire.comLisata Extends Kuva Labs Acquisition Term Sheet TimelineFebruary 27, 2026 | tipranks.comLisata Therapeutics (LSTA) price target decreased by 26.92% to 9.69February 4, 2026 | msn.comLisata Therapeutics ends Qilu certepetide collaboration dealJanuary 27, 2026 | tipranks.comLisata regains China rights to pancreatic cancer drugJanuary 27, 2026 | proactiveinvestors.comLisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideJanuary 27, 2026 | globenewswire.comBrookline Capital downgrades Lisata Therapeutics (LSTA)January 22, 2026 | msn.comAll-Cash Buyout Sparks Breakout Move in Biotech NameJanuary 22, 2026 | theglobeandmail.comHow The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation OutlookJanuary 22, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Crucial Aerospace Component Makers That Analysts LoveBy Nathan Reiff | May 16, 2026Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1By Leo Miller | May 18, 2026How Berkshire’s New York Times Bet Looks TodayBy Leo Miller | May 14, 2026Berkshire Sells Visa, Domino's, and Pool Corp: Should You Follow?By Dan Schmidt | May 26, 2026Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence?By Ryan Hasson | June 2, 2026IMNN, INMB, ATHA, and LSTA Company DescriptionsAthira Pharma NASDAQ:ATHA$8.22 -0.39 (-4.53%) As of 06/5/2026Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Imunon NASDAQ:IMNN$2.02 +0.01 (+0.50%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$2.10 +0.08 (+3.86%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.INmune Bio NASDAQ:INMB$1.22 -0.02 (-1.61%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$1.25 +0.03 (+2.05%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Lisata Therapeutics NASDAQ:LSTA$3.46 -0.02 (-0.57%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$3.70 +0.24 (+7.05%) As of 08:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass Optical Cable Corporation: Strong Earnings, But Hurdles Remain The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
